Innate immune mechanisms of colitis and colitis-associated colorectal cancer

Nature Reviews Immunology

Volumn 11, Issue 1, 2011, Pages 9-20

  Saleh, Maya ^a   Trinchieri, Giorgio ^b  

^a MCGILL UNIVERSITY   (Canada)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COLITIS; COLORECTAL CANCER; COMMENSAL; DISEASE ASSOCIATION; HUMAN; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; INTESTINE FLORA; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMALS; COLITIS; COLORECTAL NEOPLASMS; HOMEOSTASIS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; INTESTINES; METAGENOME; MICE; RATS;

EID: 78650624793     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2891     Document Type: Article

References (130)

1. Economou, M. & Pappas, G. New global map of Crohn's disease: genetic, environmental, and socioeconomic correlations. Inflamm. Bowel Dis. 14, 709-720 (2008).
2. Shanahan, F. & Bernstein, C. N. The evolving epidemiology of inflammatory bowel disease. Curr. Opin. Gastroenterol. 25, 301-305 (2009).
3. Cohen, R. D. The pharmacoeconomics of biologic therapy for IBD. Nature Rev. Gastroenterol. Hepatol. 7, 103-109 (2010).
4. De Silva, S., Devlin, S. & Panaccione, R. Optimizing the safety of biologic therapy for IBD. Nature Rev. Gastroenterol. Hepatol. 7, 93-101 (2010).
5. Yan, F. & Polk, D. B. Probiotics: progress toward novel therapies for intestinal diseases. Curr. Opin. Gastroenterol. 26, 95-101 (2010).
6. Weinstock, J. V. & Elliott, D. E. Helminths and the IBD hygiene hypothesis. Inflamm. Bowel Dis. 15, 128-133 (2009).
7. Eaden, J. A., Abrams, K. R. & Mayberry, J. F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48, 526-535 (2001).
8. Von Roon, A. C. et al. The risk of cancer in patients with Crohn's disease. Dis. Colon Rectum 50, 839-855 (2007).
9. Rutter, M. D. et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 130, 1030-1038 (2006).
10. Feagins, L. A., Souza, R. F. & Spechler, S. J. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nature Rev. Gastroenterol. Hepatol. 6, 297-305 (2009).
11. Kamangar, F., Dores, G. M. & Anderson, W. F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24, 2137-2150 (2006).
12. Tomatis, L. (ed.) Cancer: Causes, Occurrence and Control. (IARC Press, 1990).
13. Mazmanian, S. K., Round, J. L. & Kasper, D. L. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453, 620-625 (2008).
14. Rescigno, M. Before they were gut dendritic cells. Immunity 31, 454-456 (2009).
15. Hand, T. & Belkaid, Y. Microbial control of regulatory and effector T cell responses in the gut. Curr. Opin. Immunol. 22, 63-72 (2010).
16. Clarke, T. B. et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nature Med. 16, 228-231 (2010).
17. Hirayama, K. et al. Effects of human intestinal flora on mutagenicity of and DNA adduct formation from food and environmental mutagens. Carcinogenesis 21, 2105-2111 (2000).
18. Garrett, W. S. et al. Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell 16, 208-219 (2009).
19. Garrett, W. S. et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 131, 33-45 (2007).
20. Garrett, W. S. et al. Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis. Cell Host Microbe 8, 292-300 (2010).
21. Ivanov, I. I. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139, 485-498 (2009).
22. Wu, H. J. et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32, 815-827 (2010).
23. Westbrook, A. M., Wei, B., Braun, J. & Schiestl, R. H. More damaging than we think: systemic effects of intestinal inflammation. Cell Cycle 8, 2482-2483 (2009).
24. Backhed, F., Manchester, J. K., Semenkovich, C. F. & Gordon, J. I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl Acad. Sci. USA 104, 979-984 (2007).
25. Brown, S. L. et al. Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J. Clin. Invest. 11 7, 258-269 (2007).
26. Walker, M. R., Patel, K. K. & Stappenbeck, T. S. The stem cell niche. J. Pathol. 217, 169-180 (2009).
27. Mankertz, J. & Schulzke, J. D. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr. Opin. Gastroenterol. 23, 379-383 (2007).
28. Su, L. et al. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 136, 551-563 (2009).
29. Johansson, M. E. et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc. Natl Acad. Sci. USA 105, 15064-15069 (2008).
30. Velcich, A. et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295, 1726-1729 (2002).
31. Van der Sluis, M. et al. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 1 31, 117-129 (2006).
32. Heazlewood, C. K. et al. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med. 5, e54 (2008).
33. Abreu, M. T. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nature Rev. Immunol. 10, 131-144 (2010).
34. Salzman, N. H. et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nature Immunol. 11, 76-83 (2010).
35. Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883-899 (2010).
36. Nenci, A. et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature 446, 557-561 (2007).
37. Steinbrecher, K. A., Harmel-Laws, E., Sitcheran, R. & Baldwin, A. S. Loss of epithelial RelA results in deregulated intestinal proliferative/ apoptotic homeostasis and susceptibility to inflammation. J. Immunol. 180, 2588-2599 (2008).
38. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007).
39. Vereecke, L. et al. Enterocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J. Exp. Med. 207, 1513-1523 (2010).
40. Zeissig, S. et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor α antibody treatment. Gut 53, 1295-1302 (2004).
41. van den Brande, J. M. et al. Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut 56, 509-517 (2007).
42. Greten, F. R. et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 11 8, 285-296 (2004).
43. Medzhitov, R. Origin and physiological roles of inflammation. Nature 454, 428-435 (2008).
44. Liew, F. Y., Xu, D., Brint, E. K. & O'Neill, L. A. Negative regulation of Toll-like receptor-mediated immune responses. Nature Rev. Immunol. 5, 446-458 (2005).
45. Lebeer, S., Vanderleyden, J. & de Keersmaecker, S. C. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nature Rev. Microbiol. 8, 171-184 (2010).
46. Hooper, L. V. & Macpherson, A. J. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nature Rev. Immunol. 10, 159-169 (2010).
47. Xiao, H. et al. The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity 26, 461-475 (2007).
48. Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. & Medzhitov, R. Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 11 8, 229-241 (2004).
49. Salcedo, R. et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J. Exp. Med. 207, 1625-1636 (2010).
50. Clevers, H. At the crossroads of inflammation and cancer. Cell 11 8, 671-674 (2004).
51. Lee, J. et al. Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nature Cell Biol. 8, 1327-1336 (2006).
52. Katakura, K. et al. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J. Clin. Invest. 11 5, 695-702 (2005).
53. Cho, J. H. The genetics and immunopathogenesis of inflammatory bowel disease. Nature Rev. Immunol. 8, 458-466 (2008).
54. Coulombe, F. et al. Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide. J. Exp. Med. 206, 1709-1716 (2009).
55. Watanabe, T., Kitani, A., Murray, P. J. & Strober, W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nature Immunol. 5, 800-808 (2004).
56. Watanabe, T. et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J. Clin. Invest. 11 8, 545-559 (2008).
57. Magalhaes, J. G. et al. Nod2-dependent Th2 polarization of antigen-specific immunity. J. Immunol. 181, 7925-7935 (2008).
58. Biswas, A. et al. Induction and rescue of Nod2-dependent Th1-driven granulomatous inflammation of the ileum. Proc. Natl Acad. Sci. USA 107, 14739-14744 (2010).
59. Wehkamp, J. et al. Reduced Paneth cell α-defensins in ileal Crohn's disease. Proc. Natl Acad. Sci. USA 102, 18129-18134 (2005).
60. Smith, A. M. et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. J. Exp. Med. 206, 1883-1897 (2009).
61. Noguchi, E., Homma, Y., Kang, X., Netea, M. G. & Ma, X. A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nature Immunol. 10, 471-479 (2009).
62. Munz, C. Enhancing immunity through autophagy. Annual Rev. Immunol. 27, 423-449 (2009).
63. Virgin, H. W. & Levine, B. Autophagy genes in immunity. Nature Immunol. 10, 461-470 (2009).
64. Rioux, J. D. et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nature Genet. 39, 596-604 (2007).
65. Hampe, J. et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nature Genet. 39, 207-211 (2007). (Pubitemid 46184351)
66. McCarroll, S. A. et al. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nature Genet. 40, 1107-1112 (2008).
67. Cooney, R. et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nature Med. 16, 90-97 (2010).
68. Travassos, L. H. et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nature Immunol. 11, 55-62 (2009).
69. Cadwell, K. et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456, 259-263 (2008).
70. Cadwell, K. et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine. Cell 141, 1135-1145 (2010).
71. Saitoh, T. et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β production. Nature 456, 264-268 (2008).
72. Le Bourhis, L., Benko, S. & Girardin, S. E. Nod1 and Nod2 in innate immunity and human inflammatory disorders. Biochem. Soc. Trans. 35, 1479-1484 (2007).
73. Petrilli, V., Dostert, C., Muruve, D. A. & Tschopp, J. The inflammasome: a danger sensing complex triggering innate immunity. Curr. Opin. Immunol. 19, 615-622 (2007).
74. Cookson, B. T. & Brennan, M. A. Pro-inflammatory programmed cell death. Trends Microbiol. 9, 113-114 (2001).
75. Labbé, K. & Saleh, M. Cell death in the host response to infection. Cell Death Differ. 15, 1339-1349 (2008).
76. Saleh, M. et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 429, 75-79 (2004).
77. Saleh, M. et al. Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice. Nature 440, 1064-1068 (2006).
78. Yeretssian, G., Labbé, K. & Saleh, M. Molecular regulation of inflammation and cell death. Cytokine 43, 380-390 (2008).
79. Villani, A. C. et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nature Genet. 41, 71-76 (2009).
80. Pizarro, T. T. et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J. Immunol. 162, 6829-6835 (1999).
81. Zhernakova, A. et al. Genetic analysis of innate immunity in Crohn's disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am. J. Hum. Genet. 82, 1202-1210 (2008).
82. Rodriguez-Bores, L., Fonseca, G. C., Villeda, M. A. & Yamamoto-Furusho, J. K. Novel genetic markers in inflammatory bowel disease. World J. Gastroenterol. 13, 5560-5570 (2007).
83. Dinarello, C. A. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin. Nephrol. 27, 98-114 (2007).
84. Sivakumar, P. V. et al. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 50, 812-820 (2002).
85. Reuter, B. K. & Pizarro, T. T. Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe? Eur. J. Immunol. 34, 2347-2355 (2004).
86. Takagi, H. et al. Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice. Scand. J. Gastroenterol. 38, 837-844 (2003).
87. Kampfer, H. et al. Lack of interferon-γ production despite the presence of interleukin-18 during cutaneous wound healing. Mol. Med. 6, 1016-1027 (2000).
88. Siegmund, B. Interleukin-18 in intestinal inflammation: friend and foe? Immunity 32, 300-302 (2010).
89. Dupaul-Chicoine, J. et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 32, 367-378 (2010).
90. Zaki, M. H. et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 32, 379-391 (2010). A demonstration of the role of NLRP3 in colitis.
91. Allen, I. C. et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 207, 1045-1056 (2010).
92. Terzic, J., Grivennikov, S., Karin, E. & Karin, M. Inflammation and colon cancer. Gastroenterology 138, 2101-2114 (2010).
93. Bollrath, J. et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15, 91-102 (2009).
94. Grivennikov, S. et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15, 103-113 (2009).
95. Neufert, C. et al. Activation of epithelial STAT3 regulates intestinal homeostasis. Cell Cycle 9, 652-655 (2010).
96. Sears, C. L. Enterotoxigenic Bacteroides fragilis: a rogue among symbiotes. Clin. Microbiol. Rev. 22, 349-369 (2009).
97. Maddocks, O. D., Short, A. J., Donnenberg, M. S., Bader, S. & Harrison, D. J. Attaching and effacing Escherichia coli downregulate DNA mismatch repair protein in vitro and are associated with colorectal adenocarcinomas in humans. PLoS ONE 4, e5517 (2009).
98. Uronis, J. M. et al. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS ONE 4, e6026 (2009).
99. Vannucci, L. et al. Colorectal carcinogenesis in germ-free and conventionally reared rats: different intestinal environments affect the systemic immunity. Int. J. Oncol. 32, 609-617 (2008).
100. Yang, L. & Pei, Z. Bacteria, inflammation, and colon cancer. World J. Gastroenterol. 12, 6741-6746 (2006).
101. Rao, V. P. et al. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res. 66, 7395-7400 (2006).
102. Westbrook, A. M., Wei, B., Braun, J. & Schiestl, R. H. Intestinal mucosal inflammation leads to systemic genotoxicity in mice. Cancer Res. 69, 4827-4834 (2009).
103. min/+ mice. Nature Med. 16, 665-670 (2010).
104. Rakoff-Nahoum, S. & Medzhitov, R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317, 124-127 (2007).
105. Swann, J. B. et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc. Natl Acad. Sci. USA 105, 652-656 (2008).
106. Naugler, W. E. et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317, 121-124 (2007).
107. Lowe, E. L. et al. Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer. PLoS ONE 5, e13027 (2010).
108. Fukata, M. et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133, 1869-1881 (2007).
109. Turovskaya, O. et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 29, 2035-2043 (2008).
110. Maeda, S. et al. Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem. Biophys. Res. Commun. 360, 394-400 (2007).
111. Ranzato, E., Patrone, M., Pedrazzi, M. & Burlando, B. Hmgb1 promotes wound healing of 3T3 mouse fibroblasts via RAGE-dependent ERK1/2 activation. Cell Biochem. Biophys. 57, 9-17 (2010).
112. Rodier, F. et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nature Cell Biol. 11, 973-979 (2009).
113. Dunn, G. P., Koebel, C. M. & Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nature Rev. Immunol. 6, 836-848 (2006).
114. Popivanova, B. K. et al. Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 11 8, 560-570 (2008).
115. Kim, J. J. et al. Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. Gastroenterology 123, 542-553 (2002).
116. Hanada, T. et al. IFNγ-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J. Exp. Med. 203, 1391-1397 (2006).
117. Garlanda, C. et al. Increased susceptibility to colitis-associated cancer of mice lacking TIR8, an inhibitory member of the interleukin-1 receptor family. Cancer Res. 67, 6017-6021 (2007).
118. min mice. Gastroenterology 139, 574-585 (2010).
119. Vaishnava, S., Behrendt, C. L., Ismail, A. S., Eckmann, L. & Hooper, L. V. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc. Natl Acad. Sci. USA 105, 20858-20863 (2008).
120. Penders, J. et al. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 11 8, 511-521 (2006).
121. Turnbaugh, P. J., Backhed, F., Fulton, L. & Gordon, J. I. Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell Host Microbe 3, 213-223 (2008).
122. Backhed, F. et al. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl Acad. Sci. USA 101, 15718-15723 (2004).
123. Backhed, F., Ley, R. E., Sonnenburg, J. L., Peterson, D. A. & Gordon, J. I. Host-bacterial mutualism in the human intestine. Science 307, 1915-1920 (2005).
124. Boivin, G. P. et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 124, 762-777 (2003).
125. Rosenberg, D. W., Giardina, C. & Tanaka, T. Mouse models for the study of colon carcinogenesis. Carcinogenesis 30, 183-196 (2009).
126. Chen, J. & Huang, X. F. The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol. Ther. 8, 1313-1317 (2009).
127. Kohno, H., Suzuki, R., Sugie, S. & Tanaka, T. β-Catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sodium sulfate. Cancer Sci. 96, 69-76 (2005).
128. Tanaka, T. et al. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci. 94, 965-973 (2003).
129. Min, a mutation in the murine Apc gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. Proc. Natl Acad. Sci. USA 90, 8977-8981 (1993).
130. Suzui, M., Okuno, M., Tanaka, T., Nakagama, H. & Moriwaki, H. Enhanced colon carcinogenesis induced by azoxymethane in min mice occurs via a mechanism independent of β-catenin mutation. Cancer Lett. 183, 31-41 (2002).